Medicare’s Part D base beneficiary premium for 2027 will be $41.33, according to the annual bid announcement the Centers for Medicare & Medicaid Services released July 28, 2026. That figure matters less for what it is than for what it replaced: the same statutory formula that produced $41.33 also produced a second, higher result — $94.06 — and federal law required CMS to publish whichever number came out lower. The gap between those two figures, more than $52 a month, shows how much cost pressure behind Part D drug coverage a temporary legal cap is currently absorbing on behalf of enrollees nationwide.
CMS did not pick $41.33 because it looked better. The agency ran the calculation required by the Inflation Reduction Act, produced two results, and published the smaller one because the statute requires it. Understanding why takes a look at how the base beneficiary premium is built — and, just as important, what it does not tell any individual Part D enrollee about the bill that will actually arrive in the mail.
How a 6 Percent Cap Beat a $94.06 Formula
CMS’s July 28, 2026 bid announcement lays out the math directly. Section 1860D-13(a) of the Social Security Act, as amended by section 11201 of the Inflation Reduction Act of 2022, requires the base beneficiary premium for 2024 through 2029 to equal the lesser of two calculations. The first takes the prior year’s base beneficiary premium and raises it by 6 percent; for 2027, that means the 2026 premium of $38.99 multiplied by 1.06, which comes to $41.33. The second calculation applies a fixed percentage, set by statute, to the 2027 national average monthly bid amount of $296.05, the enrollment-weighted average of what Part D plan sponsors bid to provide basic drug coverage next year. That second calculation produced $94.06.
Because the statute instructs CMS to use whichever calculation is lower, the 6 percent cap won. Had the cap not existed, the base beneficiary premium would have jumped from $38.99 to $94.06 in a single year, an increase of more than 140 percent. Instead it rose to $41.33, an increase of about 6 percent. The stabilization is not a policy CMS renews at its own discretion; it is a statutory formula written into law through 2029, after which the cap is scheduled to expire and the calculation reverts to whichever of the two results the underlying bid data produces.
Free retirement updates: One number can cost or save hundreds a month in retirement. The free Retirement Shield newsletter surfaces the ones worth knowing. Sign up free.
What the Base Beneficiary Premium Actually Measures
Despite the attention the number gets, the base beneficiary premium is not a price tag anyone pays. CMS describes it as “the starting point for calculating a plan-specific basic Part D premium” — a benchmark used inside a formula, not a bill. A footnote attached to the July 28 announcement states the point even more directly: actual Part D premiums paid by individual beneficiaries equal the base beneficiary premium adjusted by several other factors, and premiums “vary significantly from one Part D plan to another and seldom equal the base beneficiary premium.”
The $296.05 national average monthly bid amount behind the calculation is itself an average across every basic Part D plan bid nationwide, weighted by enrollment in the reference month of June 2026. It does not describe what a plan in a given state, city, or pharmacy network will charge; it describes the systemwide baseline CMS uses to calculate subsidies and set the base beneficiary premium each year. Two people enrolled in different plans in the same city can end up with very different premiums even though both plans are measured against the identical $41.33 benchmark.
Why an Actual Drug Plan Bill Depends on the Plan, Not This Number
Medicare’s own consumer guidance on what Part D coverage costs is direct about where an actual premium comes from: it depends on the plan chosen, and it can be higher depending on income. Plans set premiums based on the difference between their individual bid and the national average monthly bid amount, then that starting figure is adjusted for any supplemental benefits the plan offers, any late-enrollment penalty owed, and — for Medicare Advantage plans that bundle drug coverage — rebates the plan applies to buy the premium down further. A Part D enrollee who qualifies for the Extra Help low-income subsidy can see the premium reduced or eliminated, subject to a regional subsidy benchmark and the $2 de minimis amount CMS set in the same July 28 announcement.
The base beneficiary premium still drives one enrollee-facing number directly: the late-enrollment penalty. Medicare calculates that penalty by multiplying 1 percent of the national base beneficiary premium by the number of full months someone went without Part D or other creditable drug coverage after becoming eligible. Because the base beneficiary premium is rising to $41.33 for 2027, anyone carrying that penalty will see it rise too, even if the plan eventually chosen has nothing else in common with the national average.
The $9.8 Billion Program That Just Stopped Propping Up Premiums
The 6 percent cap is not the only thing that has been holding Part D premiums down. CMS’s July 28 announcement also confirmed the end of the Part D Premium Stabilization Demonstration, a separate program the agency ran in 2025 and 2026 because the statutory cap alone was not going to be enough. A Government Accountability Office review of the demonstration found that without it, monthly premiums for standalone Part D plans would have nearly doubled on average between 2024 and 2025, with 37 percent of affected beneficiaries facing increases of more than $40 a month — increases CMS officials worried would push large numbers of enrollees to abandon their plans and disrupt access to medications. To prevent that, CMS reduced premiums by up to $15 in 2025, capped plan-level premium increases at $35, and, by GAO’s accounting, spent a combined $9.8 billion stabilizing the market over the two years.
CMS’s own bid analysis found that Part D plan sponsors now have enough experience under the Inflation Reduction Act’s redesigned drug benefit to price their 2027 plans without that extra support, so the demonstration ends after 2026 and the program returns to what CMS calls “traditional market conditions” for 2027. The base beneficiary premium’s 6 percent statutory cap remains in place through 2029, but the separate cushion that limited individual plan-level increases during the transition is now gone — part of why actuaries are watching how widely 2027 plan premiums spread once real bids are finalized.
When the Real 2027 Numbers Arrive
The $41.33 base beneficiary premium, the $296.05 national average monthly bid amount, and the $2 de minimis amount are, in CMS’s own words, preliminary technical figures meant to help plan sponsors finalize their offerings, not the retail numbers a household comparing plans will eventually see. CMS has said it will publish the 2027 Medicare Advantage and Part D landscape, along with final average premiums plan by plan, in mid-to-late September, once every plan sponsor’s bid is locked in. Until that release, no one, including CMS, can say what a specific Part D or Medicare Advantage drug plan will actually charge in 2027 — only that the formula setting the systemwide floor for that pricing stayed capped at $41.33 instead of climbing to $94.06.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
